The Board of Directors of the Company, in their meeting held today i.e. on 30th May, 2025, interalia, has: 1. Approved the Standalone Audited Financial Statements of the Company for Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab's board approved its audited standalone financial results for Q4 and FY ended 31st March, 2025, with an unmodified auditor opinion from Shah & Shah Associates. Full-year revenue from operations rose modestly to Rs. 173.30 crore (from Rs. 167.82 crore, ~3.3% growth), but profit after tax fell sharply to Rs. 8.08 crore from Rs. 11.16 crore (~28% decline), pulling EPS down to Rs. 5.82 from Rs. 8.04. Q4 was particularly weak, with PAT dropping to Rs. 0.71 crore from Rs. 2.73 crore a year ago. The board has recommended a final dividend of Rs. 1.50 per share (15%) subject to shareholder approval. The company also disclosed a pending GST demand of Rs. 12.09 crore (received in Q3 FY25) which it is contesting before CESTAT, and reported routine related party transactions.
Revenue growth was tepid while costs surged (total expenses up ~6.8%), squeezing margins and dragging PAT down nearly 28% for the full year — a negative earnings outcome for shareholders despite a steady dividend. The pending Rs. 12.09 crore GST dispute is a material overhang, though the company expects a favourable ruling; investors should watch the CESTAT appeal.